Hepatocellular carcinoma (HCC) remains a major public health problem. Transarterial
chemoembolization (TACE) is recognized as the standard of care for patients with …

Transcatheter arterial therapies for hepatocellular carcinoma (HCC) have developed during
the last decade. A fine powder formulation of cisplatin and the new platinum agent miriplatin …

Aim Balloon‐occluded transcatheter arterial chemoembolization (B‐TACE) using a
microballoon catheter was performed to administrate miriplatin, and the early therapeutic …

Background/Aim: We examined tumor marker levels to assess in more detail transcatheter
arterial chemoembolization (TACE)-refractory hepatocellular carcinoma (HCC). Materials …

A series of platinum (II) complexes, characteristic of chiral trans-bicyclo [2.2. 2] octane-7, 8-
diamine as ligand possessing dicyclic steric hindrance, were designed and synthesized …

Aim The goal of the study was to evaluate the efficacy and safety of balloon‐occluded
transarterial chemoembolization (B‐TACE) of hepatocellular carcinoma (HCC) using …

The management of hepatocellular carcinoma (HCC) is based on a multidisciplinary
decision tree. Treatment includes loco-regional therapy, mainly transarterial …

Background For advanced hepatocellular carcinoma (HCC), surgical treatment after
sorafenib induction has rarely been reported. We examined the survival benefit of additional …

Aim The aim of this study is to clarify the usefulness and limitations of balloon‐occluded
transcatheter arterial chemoembolization (B‐TACE) using miriplatin for patients with four or …

Aim Transcatheter arterial chemoembolization (TACE) and transarterial infusion
chemotherapy (TAI) are the main therapeutic strategies for treatment of advanced …